Developments in immunohistochemistry for diagnostic cellular pathology
Wednesday, 03 December 2014
Cineworld: The O2, London, SE10 0DX, UK
This event will discuss developments in Immunohistochemistry (IHC) techniques and technology to aid the improvements needed to boost and strengthen the use of IHC in future diagnostic pathology practice
This event has CPD accreditation and is part of
The 2014 Pathology Congress, 2nd – 4th December 2014 – www.pathology2014.com
Who Should Attend
Attendance is recommended to all professionals (including students) within the diagnostic and research communities that engage in immunohistochemistry.
The Deadline for abstract submissions for oral presentation is August 10th 2014
Abstracts for poster presentation only can be submitted up to two weeks before the event
You can download the instructions for authors at
www.euroscicon.com/AbstractsForOralAndPosterPresentation.pdf
Talks include
Prion as a marker in human cancers
Dr Man-Sun Sy, Professor of Pathology, Department of Pathology, Case Wesstern Reserve University, Cleveland, OH USA
The normal cellular prion protein, PrP, is a highly conserved and wildly expressed protein in mammlian cells. Over the last decades, studies in PrP has been focused on the role it plays in the pathogenesis of prion diseases, a group of fatal neurodegenerative diseases. Recently, we discovered that while normal pancreatic ductal cells do not express PrP, a group of patients with pancreatic ductal cell adenocarcinoma expressed high levels of PrP. Most importantly, expression of PrP is a marker of poor prognosis. In addtion, PrP is also detected in a subgroup of patients with prostate cancers as well as in a sunbgroup of patients with invasive melanomas.
Application of the Nanotechnology in Immunohistochemical Staining Procedures
Dr Weiming Xu, CEO London Biotech Ltd and Department of Molecular Biology and Biotechnology, University of Sheffield, UK
Development of cancer biomarkers for early and rapid diagnosis is desirable as most tumour only be detected when they contain millions of cells that may already have metastasized. Current diagnostic techniques such as peroxidase-based immunohistochemical staining procedures are labour intensive, time consuming, expensive, in need of multiple amplifications and don’t have multiplexing capability. Recent development on semiconductor nanocrystal quantum dots (QDs), has hold particular new promise as next generation of fluorescent probes. In this talk, I will present some of our latest findings on using the unfolded protein response (UPR) marker antibodies, such as anti- the glucose-regulated protein 78 (Grp78) antibody for prostate cancer and breast cancer detection and their potential usages for chemoresponsiveness and metastases in breast cancer tissue.
Additional Confirmed Speakers
Assistant Professor Paola Di Carlo, Department of Sciences for Health Promotion and Mother-Child Care, University of Palermo, Italy
Dr Esther Diana Rossi, MD PhD MIAC, Catholic University of Sacred Heart, Italy
